Ranibizumab Ophthalmic Dosage

Medically reviewed by Drugs.com. Last updated on Oct 31, 2023.

Usual Adult Dose for Macular Degeneration

Maintenance dose: 0.5 mg intravitreally once a month (approximately 28 days)

Uses: Neovascular (Wet) Age-Related Macular Degeneration (AMD), Myopic Choroidal Neovascularization (mCNV)

Usual Adult Dose for Diabetic Retinopathy

• DME and Diabetic Retinopathy:

Maintenance dose: 0.3 mg intravitreally once a month (approximately 28 days)

Uses: Diabetic macular edema (DME); Diabetic Retinopathy (DR)

• Macular Edema following RVO:

Maintenance dose: 0.5 mg intravitreally once a month (approximately 28 days)

Use: Macular Edema Following Retinal Vein Occlusion (RVO)

Usual Adult Dose for Macular Edema

• DME and Diabetic Retinopathy:

Maintenance dose: 0.3 mg intravitreally once a month (approximately 28 days)

Uses: Diabetic macular edema (DME); Diabetic Retinopathy (DR)

• Macular Edema following RVO:

Maintenance dose: 0.5 mg intravitreally once a month (approximately 28 days)

Use: Macular Edema Following Retinal Vein Occlusion (RVO)

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available.

Dose Adjustments

Although Not as Effective, the Following Dosing Regimens May Be Used in Patients with Neovascular (Wet) AMD:

• Administer 3 monthly doses followed by less frequent dosing with regular assessment. In the 9 months after 3 initial monthly doses, less frequent dosing with 4 to 5 doses on average is expected to maintain visual acuity while monthly dosing may be expected to result in an additional average 1 to 2 letter gain.

• Administer 1 dose every 3 months after 4 monthly doses with regular assessment. Compared with continued monthly dosing, dosing every 3 months over the next 9 months will lead to an approximate 5-letter (1-line) loss of visual acuity benefit on average.

Precautions

CONTRAINDICATIONS:

• Hypersensitivity to the active component or any of the ingredients
• Patients with ocular or periocular infections

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available.

Other Comments

Administration Advice:

• This drug is for ophthalmic intravitreal injection only.
• Each vial or prefilled syringe should only be used for treatment of a single eye; use of more than one injection can lead to contamination and subsequent infection.
• Adequate anesthesia and a broad-spectrum microbicide should be given prior to the injection.

Storage Requirements:

• This drug should be refrigerated at 2C to 8C (36F to 46F) protected from light and stored in its original carton until time of use. Do not freeze.

Preparation Techniques:

• The manufacturer product information should be consulted on proper drug preparation and injection procedure.

General:

• This drug is produced by an Escherichia coli expression system in a nutrient medium containing tetracycline; tetracycline is not detectable in the final product.

Monitoring:

• Intraocular pressure using tonometry (prior to and 30 minutes following injection)
• Perfusion of the optic nerve head (immediately after injection)
• Symptoms of endophthalmitis (following injection)

Patient Advice:

• Seek immediate care from an ophthalmologist if your eye becomes red, painful, sensitive to light, or develops a change in vision.

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer